AI Article Synopsis
- The rise of antibiotic-resistant bacteria poses a significant threat to public health, while new antibiotic discoveries are decreasing, mostly introducing familiar drugs in different forms.
- Researchers developed a new class of safe antimicrobials targeting a specific ion channel in bacteria, with one compound, compound 10, showing effectiveness against methicillin-resistant Staphylococcus aureus without harming human cells.
- In tests, compound 10 not only worked well in lab setups but also successfully cured infections in a model organism, demonstrating the potential of targeting this ion channel for treating antibiotic-resistant infections.
Article Abstract
The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the bacteria-specific mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are potentially important therapeutics against antibiotic-resistant bacterial infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430313 | PMC |
| http://dx.doi.org/10.1038/ja.2015.4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An effective drug-free hydrogel for accelerating the whole healing process of bacteria-infected wounds.
Biomater Sci
December 2024
Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Wound healing is a dynamic and complex process involving hemostasis, inflammation, fibroblast proliferation, and tissue remodeling. This process is highly susceptible to bacterial infection, which often leads to impaired and delayed wound repair. While antibiotic therapy remains the primary clinical approach for treating bacteria-infected wounds, its widespread use poses a significant risk of developing bacterial resistance.
View Article and Find Full Text PDF'Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' - Author's reply.
Clin Microbiol Infect
December 2024
Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address:
Green-synthesized α-FeO-nanoparticles as potent antibacterial, anti-biofilm and anti-virulence agent against pathogenic bacteria.
BMC Microbiol
December 2024
Department of Physics, College of Science, University of Halabja, Halabja, Kurdistan Region, Iraq.
Background: Antimicrobial resistance (AMR) presents a serious threat to health, highlighting the urgent need for more effective antimicrobial agents with innovative mechanisms of action. Nanotechnology offers promising solutions by enabling the creation of nanoparticles (NPs) with antibacterial properties. This study aimed to explore the antibacterial, anti-biofilm, and anti-virulence effects of eco-friendly synthesized α-Fe₂O₃ nanoparticles (α-Fe₂O₃-NPs) against pathogenic bacteria.
View Article and Find Full Text PDFStructural and Functional Mimicry of the Antimicrobial Defensin Plectasin by Analogues with Engineered Backbone Composition.
Chembiochem
December 2024
University of Pittsburgh, Department of Chemistry, 219 Parkman Ave., 15260, Pittsburgh, UNITED STATES OF AMERICA.
The threat posed by bacteria resistant to common antibiotics creates an urgent need for novel antimicrobials. Non-ribosomal peptide natural products that bind Lipid II, such as vancomycin, represent a promising source for such agents. The fungal defensin plectasin is one of a family of ribosomally produced miniproteins that exert antimicrobial activity via Lipid II binding.
View Article and Find Full Text PDFAntimicrobial peptide LL37 is potent against non-growing cells despite a slower action rate.
mSphere
December 2024
Department of Physics and Astronomy, California State University, Northridge, California, USA.
Unlabelled: Antimicrobial peptides (AMPs) have long been considered as potential agents against non-growing, dormant cells due to their membrane-targeted action, which is largely independent of the cell's growth state. However, the relationship between the action of AMPs and the physiological state of their target cells has been unclear, with recent reports offering conflicting views on the efficacy of AMPs against bacteria in a stationary phase. In this study, we employ single-cell approaches combined with population-level experiments to examine the action of human LL37 peptides against cells in different growth phases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!